Corporate Profile
The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. At Candel Therapeutics, we are developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease.
Minimum 15 minutes delayed. Source:
News Releases
Nov 14, 2024
Nov 07, 2024
Nov 05, 2024
Events
Nov 20, 2024
Jun 25, 2024 at 3:00 PM EDT
Jun 5, 2024 at 5:30 PM EDT
SEC Filings
Filing date | Description | Form |
---|---|---|
Report of unscheduled material events or corporate event |
8-K | |
Quarterly report which provides a continuing view of a company's financial position |
10-Q | |
Statement of changes in beneficial ownership of securities |
4 |